drugset / Trial / NCT00382733
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
Phase 1/2
Completed
26 enrolled
Accelerated Community Oncology Research Network
GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness of oral topotecan and how well the chemotherapy is tolerated (any side effects) when it is given in different dose levels. The study will also collect information on how the medication is being broken down and absorbed in the body and how quality of life is affected during treatment.
Timeline
- Start
- 2006-11
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | 0.25 mg | Oral |
| Subject | Topotecan | Small molecule | 0.5 mg | Oral |
| Subject | Topotecan | Small molecule | 0.75 mg | Oral |
| Subject | Topotecan | Small molecule | 1 mg | Oral |
| Subject | Topotecan | Small molecule | 1.25 mg | Oral |